Toolkit for Nucleosome & Histone Research
AMSBIO has announced addition of new biotinylated histones and nucleosomes to its expanding range of recombinant nucleosomes, purified nucleosomes and full length histone proteins.
A nucleosome is the basic unit of DNA packaging. It consists of a segment of DNA wound around a core ('octamer') of eight histone proteins (two each of histones H2A, H2B, H3, and H4). The 'tails' of these histone proteins stick out, where they can be modified by a number of different histone acetyltransferases, methyltransferases, PARPs, and other epigenetic enzymes. Many of these enzymes modify very specific sites; for example, EZH2, specifically tri-methylates the lysine at position 27 in the H3 histone.
AMSBIO's new line of biotinylated histone peptides have been developed for enzyme kinetic studies, as well as for screening small molecular inhibitors of different histone methyltransferases in drug discovery and HTS applications.
The major difference between AMSBIO recombinant nucleosomes made in E. coli and those purified from whole cells is that the recombinant ones are unmodified. E. coli and other bacteria do not have the enzymes to methylate or acetylate the histone proteins. AMSBIO nucleosomes purified from mammalian cells are supplied methylated or acetylated on most histone sites, making them suitable substrates for demethylases.
For further information on the complete range of nucleosomes and histones available from AMSBIO please visit www.amsbio.com/Nucleosomes-and-Histone-Proteins.aspx
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...